10-Q: BullFrog AI Q1 2026 Earnings: Focus on Funding and Nasdaq Compliance

BullFrog AI Holdings, Inc. reports Q1 2026 results, highlighting increased cash reserves from equity financing, ongoing efforts to regain Nasdaq compliance, and continued R&D investment.

Summary

• BullFrog AI Holdings, Inc. reported its first quarter 2026 financial results, ending March 31, 2026.
• The company's cash and cash equivalents significantly increased to $5,080,463 from $2,183,705 at the end of 2025, largely due to proceeds from equity financing.
• Total operating expenses decreased to $1,614,627 from $2,056,620 in the prior year's comparable period, driven by reductions in R&D and G&A expenses.
• The company continues to address Nasdaq listing requirements, having regained compliance with the Stockholders Equity Rule as of April 21, 2026, though it will be subject to a one-year monitoring period.
• BullFrog AI is also working to regain compliance with the minimum bid price requirement ($1.00) by August 10, 2026, exploring options including a potential reverse stock split.
• The company has a feasibility agreement with a global pharmaceutical company for its bfLEAP platform and is in discussions with other potential partners.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment due to the continued net losses and the ongoing challenges with Nasdaq listing compliance, despite positive developments in cash position and operational expense reduction.

Positives

• Cash and cash equivalents increased significantly to $5,080,463 as of March 31, 2026, up from $2,183,705 as of December 31, 2025, bolstered by $4.5 million in net proceeds from equity financings (ATM and ELOC facilities).
• Total operating expenses decreased by $441,993 to $1,614,627 for the three months ended March 31, 2026, compared to $2,056,620 for the same period in 2025.
• Regained compliance with the Nasdaq Stockholders Equity Rule as of April 21, 2026, following a hearing with the Nasdaq Hearings Panel.
• Secured a feasibility agreement with a global pharmaceutical company in March 2026 to apply its bfLEAP platform for drug target discovery.
• The company has a cash runway expected to fund operations for at least one year beyond the filing date.

Negatives

• The company reported a net loss of $1,593,161 for the three months ended March 31, 2026, compared to a net loss of $2,017,553 for the same period in 2025.
• Net loss per common share was $(0.12) for the three months ended March 31, 2026, compared to $(0.21) for the same period in 2025.
• The company is still not in compliance with the Nasdaq minimum bid price requirement ($1.00) and has until August 10, 2026, to regain compliance.
• The company's ability to continue as a going concern is subject to substantial doubt due to its history of net losses and reliance on future financing.
• The issuance of additional equity securities may be significantly dilutive to current shareholders.

Risks

• The company's ability to continue as a going concern is subject to substantial doubt, dependent on securing additional financing or generating sufficient revenues.
• Failure to regain compliance with Nasdaq's minimum bid price requirement by August 10, 2026, could lead to delisting.
• The company may need to seek additional capital sooner than expected if actual results differ from management's estimates.
• The company is subject to a mandatory panel monitor for one year from April 21, 2026, for Nasdaq Stockholders Equity Rule compliance.
• Future equity issuances could be significantly dilutive to existing shareholders.
• The company's success depends on its ability to attract and retain customers, secure financing, and effectively manage growth and expenses.

Future Outlook

The company anticipates seeking additional capital to continue executing its strategy, which includes generating revenue through strategic relationships, acquiring rights to late-stage failed drugs, and potentially conducting late-stage clinical trials. Management believes current cash and cash equivalents are sufficient to fund planned operations for at least one year, but this is subject to significant assumptions and uncertainties. The company is actively monitoring its Nasdaq listing requirements and exploring options to regain compliance.

Management Comments

• Management has evaluated the Company's liquidity and concluded that, as of March 31, 2026, while current cash and cash equivalents are expected to be sufficient to fund the Company's planned operations for at least a year beyond the filing date of the consolidated financial statements, such forecast is subject to significant assumptions and uncertainties.
• If actual results differ from management's estimates, the Company may need to seek additional capital sooner than expected.
• The ability to continue as a going concern is dependent upon us utilizing the financing facilities available to us or obtaining necessary additional financing or revenues to meet our obligations arising from normal business operations when they become due.
• We intend to monitor the closing bid price of its Common Stock and assess potential options to regain compliance with Nasdaqs Listing Rules, including, if necessary, effecting a reverse stock split.

Industry Context

StockSavvy.ai notes that BullFrog AI's focus on AI/ML for drug development aligns with a significant trend in the pharmaceutical industry, where companies are increasingly leveraging advanced technologies to accelerate R&D, reduce costs, and improve success rates in drug discovery and clinical trials. The company's partnerships with academic institutions like JHU-APL and GWU, and its feasibility agreement with a global pharmaceutical company, are strategic moves to validate and commercialize its technology in a competitive landscape.

Comparison to Industry Standards

• The company's net loss of $1,593,161 for the quarter is typical for early-stage biotech/AI companies investing heavily in R&D and platform development, where revenue generation is often in its nascent stages.
• The significant increase in cash reserves through equity financing ($4.5 million net proceeds) is a common strategy for companies in this sector to fund ongoing operations and development, though it carries dilution risks.
• The ongoing efforts to maintain Nasdaq listing compliance, particularly the bid price requirement, are a challenge faced by many smaller, growth-oriented companies in the biotech and technology sectors.
• The company's strategy of licensing technology from academic institutions (JHU-APL, GWU) and forming partnerships (LIBD, Sygnature, global pharma client) is a standard approach in the biotech industry to de-risk drug development and leverage specialized expertise.

Legal Proceedings

• To the best of the company's knowledge, there are no current legal proceedings that are material to its financial condition or results of operations.

Stakeholder Impact

• Shareholders may experience dilution due to ongoing equity financings and potential future stock issuances.
• The company's ability to regain Nasdaq compliance is crucial for maintaining investor confidence and market liquidity.
• Employees and consultants are subject to the company's ongoing financial performance and ability to secure funding for operations and development.
• Partners and collaborators (e.g., JHU-APL, GWU, LIBD, global pharma client) are impacted by the company's progress in advancing its AI/ML platform and drug development programs.

Next Steps

• Regain compliance with Nasdaq's minimum bid price requirement by August 10, 2026.
• Continue to monitor and maintain compliance with Nasdaq listing rules, including the Stockholders Equity Rule under a one-year panel monitor.
• Execute on the feasibility agreement with the global pharmaceutical company.
• Pursue additional strategic partnerships and collaborations for revenue generation and drug development.
• Explore options, including a potential reverse stock split, to address the minimum bid price requirement.

Key Dates

Recommendation

The company shows progress in securing funding and regaining Nasdaq compliance on one front, but the continued net losses, reliance on future financing, and the outstanding Nasdaq bid price issue present significant risks. The potential for dilution from ongoing capital raises also warrants caution. A 'hold' recommendation reflects the speculative nature of the company's development stage and the balance of positive and negative factors.

Keywords

BullFrog AI, SEC Filing, 10-Q, Quarterly Report, AI in Healthcare, Drug Development, Nasdaq Compliance, Financing